Takeda pursuing exosome therapies through Evox deal

Takeda is betting on Evox’s exosome drug delivery technology via a partnership to develop five protein replacement and mRNA therapies for rare diseases.

Evox Therapeutics Ltd., an Oxford, U.K.-based biotech, is eligible to receive up to $882 million in payments, including $44 million in an upfront payment, near-term milestones and research funding, plus tiered royalties. ...